Ibrutinib for bridging to allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is safe and effective: Updated results of a study by the EBMT Chronic Malignancy and Lymphoma Working Parties, the French Cooperative Group for CLL, and the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)

Authors

Dreger P; Michallet M; Bosman P; Sobh M; Boumendil A; Nagler A; Scheid C; Cornelissen J; Mueller L; Niederwieser D

pp. S99-S99

NATURE PUBLISHING GROUP

July 2017

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT)

FRANCE, Marseille

March 26, 2017

March 29, 2017

BONE MARROW TRANSPLANTATION

0268-3369

Tobias Berg